International scoring system for evaluating prognosis in myelodysplastic syndromes.
暂无分享,去创建一个
T Hamblin | G. Mufti | P. Greenberg | D. Oscier | P. Morel | P. Fenaux | M. Sanz | T. Hamblin | K. Ohyashiki | G. Sanz | C. Aul | T. Vallespí | P Fenaux | P Greenberg | C Cox | M M LeBeau | P Morel | G Sanz | M Sanz | T Vallespi | D Oscier | K Ohyashiki | K Toyama | C Aul | G Mufti | J Bennett | M. Lebeau | K. Toyama | C. Cox | John M. Bennett | J. Bennett | G. Mufti | Keisuke Toyama | Kazuma Ohyashiki | Ghulam J. Mufti | Pierre Fenaux | Michelle M. LeBeau | Peter L. Greenberg | Christopher Cox | Pierre Morel | Guillermo Sanz | Teresa Vallespi | David Oscier | C. Aul | John M. Bennett
[1] M. Sanz,et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.
[2] D. Oscier. Myelodysplastic syndromes. , 2007, Bailliere's clinical haematology.
[3] M. Oken,et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia , 1988, British journal of haematology.
[4] R. Larson,et al. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. , 1988, Leukemia.
[5] H. Gralnick,et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group , 1994, British journal of haematology.
[6] A. Julià,et al. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification , 1985, British journal of haematology.
[7] S. Asano,et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. , 1993, Leukemia.
[8] D. Hossfeld,et al. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. , 1990, Cancer genetics and cytogenetics.
[9] J. Rowley,et al. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes , 1986 .
[10] D. Machin,et al. Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.
[11] D. Rosenthal,et al. Chronic myelomonocytic leukemia. , 1990, Leukemia.
[12] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.
[13] C. Declercq,et al. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very‐low‐risk group using standard mortality ratio techniques , 1996, British journal of haematology.
[14] O. Garson,et al. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. , 1994, Leukemia.
[15] B. Coiffier,et al. Dysmyelopoietic syndromes a search for prognostic factors in 193 patients , 2006, Cancer.
[16] G. Tricot,et al. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations , 1985, British journal of haematology.
[17] J. Armitage,et al. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases , 1985, Cancer.
[18] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .
[19] K. United. Loss of the Y chromosome from normal and neoplastic bone marrows , 1992, Genes, chromosomes & cancer.
[20] E. Wattel,et al. De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? , 1993, Leukemia research.
[21] G. Tricot,et al. The 5q-anomaly. , 1985, Cancer genetics and cytogenetics.
[22] H. Berghe,et al. A new hematologic syndrome with a distinct karyotype: the 5 q--chromosome. , 1975, Blood.
[23] G. Tricot,et al. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis , 1985, British journal of haematology.
[24] A. Duhamel,et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.
[25] J. Hermans,et al. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases , 1987, British journal of haematology.
[26] M. Pfeilstöcker,et al. Cross‐validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics , 1999, British journal of haematology.
[27] M. Sanz,et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors , 1990, British journal of haematology.
[28] R. Beuscart,et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Rowley,et al. Clinical-cytogenetic correlations in myelodysplasia (preleukemia). , 1989, Cancer genetics and cytogenetics.
[30] D. Oscier. 5 Myelodysplastic syndromes , 1987 .
[31] U. Germing,et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.